推薦: 檢驗(yàn)設(shè)備 | 影像設(shè)備 | 手術(shù)/急救設(shè)備 | 超聲設(shè)備 | 電子儀器 | 激光儀器 | 治療康復(fù)設(shè)備 | 病房護(hù)理設(shè)備 | 醫(yī)用光學(xué) | 冷療/冷藏設(shè)備 | 實(shí)驗(yàn)室設(shè)備 | 幻燈課件 | 臨床用藥 |
![]() |
首頁(yè) > 美迪醫(yī)訊 > Integra公司研制出神經(jīng)監(jiān)測(cè)NeuroSensor系統(tǒng) |
Integra公司研制出神經(jīng)監(jiān)測(cè)NeuroSensor系統(tǒng) 【?2004-11-22 發(fā)布?】 美迪醫(yī)訊
美國(guó)Integra公司研制出腦外傷患者神經(jīng)監(jiān)測(cè)NeuroSensor系統(tǒng) 這種被稱作NeuroSensor(“神經(jīng)感受器”)的系統(tǒng)操作簡(jiǎn)便,臨床醫(yī)生只要將單個(gè)導(dǎo)管插入一個(gè)不起眼的螺栓中,就可以同步測(cè)量患者的大腦血流和顱內(nèi)壓。這個(gè)系統(tǒng)允許外科醫(yī)生實(shí)時(shí)監(jiān)測(cè)相關(guān)的生命體征,允許持續(xù)定量檢測(cè)患者腦部缺血的風(fēng)險(xiǎn),允許在外傷或者腦外科手術(shù)等腦實(shí)質(zhì)創(chuàng)傷之后,直接檢測(cè)顱內(nèi)壓。檢測(cè)系統(tǒng)使用激光多普勒流式儀技術(shù)測(cè)量腦部血流,而使用微電子機(jī)械系統(tǒng)(microelectromechanical system,MEMS)測(cè)量顱內(nèi)壓。通過(guò)檢測(cè)可以導(dǎo)致顱內(nèi)壓升高的病變,比如大腦血流的某些特定變化,從而可以預(yù)防進(jìn)一步的腦損傷,或者將這種損傷限制在最小范圍內(nèi)。 美國(guó)新澤西州Integra生命科學(xué)儲(chǔ)備公司(Plainsboro, NJ, USA)高級(jí)副總裁Deborah Leonetti說(shuō):“我們的目標(biāo)是提供在線和實(shí)時(shí)的多峰形性監(jiān)測(cè)作為監(jiān)測(cè)標(biāo)準(zhǔn),這促使了神經(jīng)監(jiān)測(cè)系統(tǒng)的研發(fā),我們?yōu)槟軌蛱峁┻@種治療和監(jiān)測(cè)神經(jīng)外傷和腦血管疾病的尖端技術(shù)而感到十分自豪。” Neuromonitoring for Brain-Injured Patients A new neuromonitoring system measures both cerebral blood flow (CBF) and intracranial pressure (ICP) in brain-injured patients. The system has been cleared by the U.S. Food and Drug Administration (FDA). Called NeuroSensor, the system is easy to use, allowing clinicians to obtain simultaneous measurements of a patient’s CBF and ICP through the use of a single catheter inserted through a low-profile bolt. The system provides relevant measurements for a surgeon on a real-time basis, allowing for continuous qualitative monitoring in patients at risk of cerebral ischemia and for the direct monitoring of ICP in intraparenchymal applications following injury or neurosurgical procedures. The sensor measures CBF using laser Doppler flowmetry technology, while ICP is measured by a microelectromechanical system (MEMS). By detecting the conditions that lead to increased ICP, such as certain changes in CBF, further injury to the brain may be prevented or limited. “Our goal is to provide online and real-time multimodality monitoring as the standard of care,” noted Deborah Leonetti, senior vice president of marketing for Integra Lifesciences Holdings Corp. (Plainsboro, NJ, USA; www.integra-ls.com), which developed the neuromonitoring system. “We are very proud to offer this cutting-edge technology for the treatment and care of patients with neurotrauma and cerebrovascular disease.” 本文關(guān)鍵字:
神經(jīng)監(jiān)測(cè)系統(tǒng)
《美迪醫(yī)訊》歡迎您參與新聞投稿,業(yè)務(wù)咨詢: 美迪醫(yī)療網(wǎng)業(yè)務(wù)咨詢
更多關(guān)于 神經(jīng)監(jiān)測(cè)系統(tǒng) 的新聞
《上海醫(yī)療器械批發(fā)》產(chǎn)品推薦
|